GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (XPAR:GNFT) » Definitions » Moat Score

Genfit (XPAR:GNFT) Moat Score : 3/10 (As of Jun. 29, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Genfit Moat Score?

Genfit has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Genfit has No Moat: Genfit operates in the biotech sector with some intellectual property, but faces significant competition and regulatory challenges. The company's market share and brand strength are not sufficient to establish a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Genfit might have No Moat - Very weak/transient advantages.


Competitive Comparison of Genfit's Moat Score

For the Biotechnology subindustry, Genfit's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genfit's Moat Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genfit's Moat Score distribution charts can be found below:

* The bar in red indicates where Genfit's Moat Score falls into.


;
;

Genfit  (XPAR:GNFT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Genfit Moat Score Related Terms

Thank you for viewing the detailed overview of Genfit's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Genfit Business Description

Traded in Other Exchanges
Address
Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Genfit Headlines

From GuruFocus

Full Year 2020 Genfit SA Earnings Presentation Transcript

By GuruFocus Research 02-07-2024

Half Year 2021 Genfit SA Earnings Call Transcript

By GuruFocus Research 02-07-2024

After Drug Failure, Genfit's Cupboard Is Nearly Bare

By Barry Cohen Barry Cohen 05-14-2020